Board of Directors
Michael Milken, M.B.A, Chairman
Fortune magazine called Mike Milken "The Man Who Changed Medicine" for his three decades of work to accelerate medical research. In 1982, he formalized his previous philanthropy by co-founding the Milken Family Foundation, a leader in worldwide research on cancer, pediatric neurological disorders, and other diseases. He heads FasterCures, which is dedicated to accelerating progress against all life-threatening diseases, and the Milken Institute, a major economic think tank. In 2007, Mike joined leading physicians in launching his latest medical initiative, the Melanoma Research Alliance, to support work on fatal skin cancers. As a financier, he is often said to have revolutionized modern capital markets. Starting in 1969, he financed thousands of companies that created millions of jobs. A graduate of UC Berkeley and the Wharton School, he and his wife, Lori, have three children and eight grandchildren. Details are at http://www.mikemilken.com
Margaret Anderson, M.A., Executive Director
Margaret Anderson is the executive director of FasterCures/The Center for Accelerating Medical Solutions, a Milken Institute center that works to speed up the timeline for new medicines to go from discovery to patients. She is a founding board member and past-president of the Alliance for a Stronger FDA, co-chairs the eHealth Initiative's Council on Data and Research, and is a member of the National Center for Advancing Translational Sciences Advisory Council, the Cures Acceleration Network Review Board, the National Health Council Board of Directors, United for Medical Research Steering Committee, and the Institute of Medicine's Forum on Drug Discovery, Development and Translation. Previously, Margaret was the deputy director and a team leader in the Center on AIDS & Community Health at the Academy for Educational Development, where she led public health projects; program director at the Society for Women's Health Research; health science analyst at the American Public Health Association, where she managed a programmatic portfolio on HIV/AIDS and other sexually transmitted diseases, infectious diseases, women's health, and public health infrastructure issues; and analyst and project director at the Congressional Office of Technology Assessment in the Biological Applications Program, where she studied societal and business implications of genetic testing. Margaret holds a bachelor's degree from the University of Maryland and a master's degree in science, technology, and public policy from George Washington University.
David Baltimore, Ph.D.
David Baltimore is a professor of biology at the California Institute of Technology and the 1975 Nobel Prize recipient for work in virology. Among his accomplishments, David was founding director of MIT's Whitehead Institute for Biomedical Research, president of Rockefeller University, and head of the National Institutes of Health AIDS Vaccine Research Committee. He helped create a consensus on national science policy regarding recombinant DNA research and established standards for genetic research. David also earned the 1970 Gustave Stern award in virology, the 1971 Eli Lilly and Co. award in microbiology and immunology, the 1999 National Medal of Science, and the 2000 Warren Alpert Foundation Prize. David earned his doctorate at Rockefeller University.
Ernest Bates, M.D.
Ernest Bates is a board-certified neurosurgeon and chairman and CEO of the American Shared Hospital Services, which he founded. American Shared Hospital Services is a publicly traded healthcare company providing services to hospitals in 22 states. Ernest received the Kjakan Award for his contribution to the spirit of entrepreneurial capitalism. He is a member of the board of University of Rochester and is an emeritus trustee of Johns Hopkins University. Ernest is also on the board at University of California, San Francisco School of Nursing, a member of The California High-Speed Rail Authority, and The Brookings Institution. Ernest earned his medical degree at the University of Rochester School of Medicine.
Leon D. Black, M.B.A.
In 1990, Leon Black founded Apollo Advisors, L.P. and Lion Advisors, L.P. to manage investment capital on behalf of a group of institutional investors, focusing on corporate restructuring, leveraged buyouts, and taking minority positions in growth-oriented companies. Since that time, Apollo and its affiliates have managed approximately $15 billion in such activities. Leon also co-founded Apollo Real Estate Advisors, L.P., which since 1993 has invested in more than $5 billion of real estate-related assets. From 1977 to 1990, Leon worked at Drexel Burnham Lambert Incorporated, where he served as managing director, head of the mergers & acquisitions group, and co-head of the corporate finance department. Leon is a director of United Rentals, Inc., Allied Waste Industries, Inc., and Sirius Satellite Radio Inc. Leon is a trustee of Dartmouth College, The Museum of Modern Art, Mt. Sinai Hospital, Lincoln Center for the Performing Arts, The Metropolitan Museum of Art, Prep for Prep, and The Asia Society. He is also a member of The Council on Foreign Relations, The Partnership for New York City, and the National Advisory Board of JPMorganChase. Leon graduated summa cum laude from Dartmouth College in 1973 with a major in philosophy and history and received a master of business administration from Harvard Business School in 1975.
Nancy G. Brinker
is regarded as the leader of the global breast cancer movement. Her journey began with a simple promise to her dying sister, Susan G. Komen, that she would do everything possible to end breast cancer, forever. In one generation, the organization that bears Susan's name has changed the world. After her sister's death from breast cancer at the age of 36, Nancy founded Susan G. Komen for the Cure® in her memory in 1982. She faced an immediate uphill battle: newspapers balked at printing the words "breast cancer," no one talked openly about the disease, few treatment options existed for breast cancer patients, and limited resources were committed to the disease. In a matter of years, Nancy broke the silence around breast cancer, and Komen for the Cure is now the world's largest grassroots network of breast cancer survivors and activists, committed to action against breast cancer through research, community health, advocacy, and global programs. To date, the organization has invested more than $1.9 billion in breast cancer research, education, screening, and treatment. Brinker's determination to create a world without breast cancer is matched by her passion for enlisting every segment of society - from leaders to citizens - to participate in the battle. In 2009, President Barack Obama honored her with the Presidential Medal of Freedom, the nation's highest civilian honor, for this work. The same year, she was named Goodwill Ambassador for Cancer Control for the United Nations' World Health Organization, where she continues her mission to put cancer control at the top of the world health agenda. She previously served as U.S. chief of protocol and U.S. ambassador to Hungary in the George W. Bush administration. She was named one of TIME magazine's "100 Most Influential People" and has received numerous accolades for her work.
Larry S. Flax has served as co-CEO since July 2003 and as co-chairman of the board since California Pizza Company's (CPK) formation in October 1985. Larry also served as co-CEO from 1985 to 1996. In January 2002, Larry co-founded LA Food Show, Inc., a family-oriented grill and bar, now a wholly-owned subsidiary of CPK, and served as co-president of that company. Prior to founding CPK, Larry practiced law as a principal in Flax and Rosenfield, Inc., after serving as an assistant United States attorney of the Department of Justice and Chief Criminal Division, and chief of the Civil Rights Division of the United States Attorney's Office in Los Angeles. Larry serves on the board of FasterCures, as well as on the board of the University of Southern California Law School.
Michael L. Klowden, J.D.
Michael Klowden is CEO of the Milken Institute. Michael joined the institute in 2001 from Jefferies & Company, then the largest institutional securities brokerage and investment banking firm in Southern California. At Jefferies, he served as vice chairman, president, and chief operating officer. Prior to joining Jefferies, Michael was a senior partner at the international law firm of Morgan, Lewis & Bockius. He served as one of the four members of that firm's management committee, was managing partner of the Los Angeles office, and was national vice chairman of the firm's business and finance practice. He is a trustee of the University of Chicago. Michael earned his law degree at Harvard Law School (ex-officio).
Shmuel Meitar is director of the Aurec Group and vice chairman of Aurec Ltd., a leading provider of communications, media, and information services. He has held the post of vice chairman since 1991 and director since 1996. Prior to that, Shmuel was president of the Aurec Group, which includes Golden Channels, the largest cable television franchise in Israel, and Golden Pages, the Israeli Yellow Pages. Shmuel has been a director of the Jerusalem Post since 1992 and also serves as a director of Golden Publications, Ltd.
Richard Merkin, M.D.
Richard Merkin is CEO and founder of Heritage Provider Network, with more than 30 years experience in managing clinically focused, administrative services organizations in healthcare delivery and physician network development. Richard pioneered the development of medical networks, many of which have been recognized for their performance and service to the community. Richard received the Marquis Award for healthcare from the Southern California Foundation for Health, Education, and Research, and he is active on the advisory board for the chairman of the Assembly Subcommittee on Health, the Healthcare Delivery Council, the Society for Physicians in Administration, and the American College of Physician Executives. Richard earned his medical degree at the University of Miami School of Medicine.
Allan Schweitzer, M.B.A.
Allan Schweitzer is an executive managing director at Beach Point Capital Management. Allan has been in the industry for 18 years, most recently as chief investment officer and senior portfolio management at Post Advisory Group, where he specialized in high yield securities. Prior to Post, Allan was a senior high yield analyst at Trust Company of the West (TCW), where he specialized in healthcare, media, and the telecommunications industries. Prior to TCW, he was an emerging market corporate credit analyst at Putnam Investments. While at Putnam, he also designed global fixed income risk models. Allan received a bachelor's degree in business administration from Washington University at St. Louis and his master of business administration from the University of Chicago with a concentration in analytical finance and international economics. He currently serves on the board of Bet Tzedek and FasterCures.
Greg Simon, J.D.
Greg Simon is the CEO of Poliwogg, an online crowd-financing marketplace that matches young companies with sophisticated investors. Poliwogg concentrates in healthcare, yield-based investments, and community enterprises. Previously, Greg was the founding president of FasterCures, held senior positions in both chambers of Congress and the White House, was a senior strategy consultant to a variety of international technology CEOs, and served as senior vice president at Pfizer for world wide policy and patient engagement.
Jonathan W. Simons, M.D.
Jonathan W. Simons is an internationally recognized physician-scientist, oncologist, and acclaimed investigator in translational prostate cancer research. Prior to joining the Prostate Cancer Foundation (PCF) in 2007, he was Distinguished Service Professor of Hematology and Oncology at the Emory University School of Medicine and professor of biomedical engineering and materials sciences at the Georgia Institute of Technology. Jonathan is the founding director of the Winship Cancer Institute at Emory University in Atlanta and co-director of the National Cancer Institute Center for Cancer Nanotechnology Excellence at Emory and Georgia Tech. Jonathan received a bachelor of arts from Princeton University and a medical degree from The Johns Hopkins University School of Medicine. Before entering medical school, he was a Rotary International Postgraduate Fellow in the Humanities at the University of Kent in Canterbury, England, and a Nuffield Foundation Fellow in the Department of Biochemistry at the University of Cambridge. Jonathan completed his residency in internal medicine at Massachusetts General Hospital at Harvard Medical School and his fellowship in medical oncology at Johns Hopkins. Jonathan has been a funded physician-scientist in prostate cancer by the National Cancer Institute, Department of Defense, PCF, and other agencies since 1990. He is also board-certified in internal medicine and medical oncology. He is married to Plum Simons, a breast cancer survivor, and has two sons.
David A. Steinberg
David A. Steinberg is founder and CEO of CAIVIS and XL Marketing. Prior to founding CAIVIS and XL Marketing, David founded InPhonic, the largest seller of wireless phones and communications products and services on the Internet, with annual revenue in excess of $400 million. InPhonic was number one on the Inc. 500 list of fastest growing companies in 2004, the year it went public on the NASDAQ. David also served as chairman and CEO of Sterling Cellular, a B2B and retail wireless communications provider, and Sterling Communications, a communications telemarketing company. David was named the Greater Washington Ernst & Young Entrepreneur of the Year for communications in 2002. He currently sits on the board of FasterCures, the Greater Washington Sports Alliance, and the Washington & Jefferson College and previously served on the board of the U.S. Chamber of Commerce. David holds a bachelor of science from Washington & Jefferson College.
Jedd Wolchok, MD
Dr. Wolchok is currently Chief of the Melanoma and Immunotherapeutics Service, Associate Attending Physician at Memorial Sloan-Kettering Cancer Center (MSKCC) with an expertise in the treatment of metastatic melanoma. Dr. Wolchok has helped establish MSKCC as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He also leads the MSKCC Immune Monitoring Facility, a world-renowned full-time core dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapeutic approaches. He is Principal Investigator of numerous ongoing clinical trials at MSKCC in the area of immunotherapy. He supervises an R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical mouse models. In 2011, I established the Immunotherapeutics Clinical Core, a specialized phase 1-2 outpatient unit at MSKCC that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies.
Dr. Wolchok has been recognized for his momentous career throughout the years and has received several of awards including the Melanoma Research Foundation – Humanitarian Award in 2010, the Melanoma International Foundation’s Doctor of the Year award in 2012, and was named the Virginia and Daniel K. Ludwig Chair for Clinical Investigation in 2013. In this year alone, he has been recognized with the American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award in April and the Giant of Cancer Care in Melanoma Award in June.
He received his undergraduate degree from Princeton University. While at New York University, he earned a bachelor’s in surgery as well as his medical and doctorate degrees. He completed his internship at the New York University Medical Center Bellevue Hospital and his fellowship at Memorial Sloan Kettering Cancer Center where he was named Chief Fellow in Medical Oncology-Hematology (1997-1998).